Skorupska Ewa, Kaźmierski Sławomir, Potrzebowski Marek J
Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences , Sienkiewicza 112, 90-363 Łodz, Poland.
Mol Pharm. 2017 May 1;14(5):1800-1810. doi: 10.1021/acs.molpharmaceut.7b00092. Epub 2017 Apr 18.
Grinding and melting methods were employed for synthesis of pharmaceutical cocrystals formed by racemic (R/S) and entiomeric (S) ibuprofen (IBU) and nicotinamide (NA) as coformer. Obtained (R/S)-IBU:NA and (S)-IBU:NA cocrystals were fully characterized by means of advanced one- and two-dimensional solid state nuclear magnetic resonance (SS NMR) techniques with very fast magic angle spinning (MAS) at 60 kHz. The distinction in molecular packing and specific hydrogen bonding pattern was clearly recognized by analysis of H, C, and N spectra. It is concluded from these studies that both methods (grinding and melting) provide exactly the same, specific forms of cocrystals. Thermal solvent-free (TSF) approach was used for loading of (R/S)-IBU:NA and (S)-IBU:NA into the pores of MCM-41 mesoporous silica particle (MSP). The progress and efficiency of this process was analyzed by NMR spectroscopy. It has been confirmed that TSF method is an effective and safe technique of filling the MSP pores with active pharmaceutical ingredients (APIs). By analyzing the NMR results, it has been further proved that excess of IBU and NA components, which are not embedded into the pores during melting and cooling, crystallize on the MCM-41 walls preserving very specific arrangement, characteristic for crystalline samples. By investigating kinetic of release for (R/S)-IBU/MCM-41, (S)-IBU:NA/MCM-41, and (R/S)-IBU:NA/MCM-41 samples containing active components exclusively inside of the pores, it was revealed that release of IBU is much faster for the first of the samples compared to those containing IBU and NA inside the pores. The hypothesis that the rate of release of API can be controlled by specific composition of cocrystal embedded into the MSP pore was further supported by study of (R/S)-IBU:BA/MCM-41 sample with benzoic acid (BA) as coformer.
采用研磨和熔融方法合成了由外消旋(R/S)和对映体(S)布洛芬(IBU)与烟酰胺(NA)作为共形成物形成的药物共晶体。通过先进的一维和二维固态核磁共振(SS NMR)技术,在60 kHz的极快速魔角旋转(MAS)条件下,对获得的(R/S)-IBU:NA和(S)-IBU:NA共晶体进行了全面表征。通过对H、C和N光谱的分析,清楚地识别出了分子堆积和特定氢键模式的差异。从这些研究中得出结论,两种方法(研磨和熔融)都能提供完全相同的特定形式的共晶体。采用无热溶剂(TSF)方法将(R/S)-IBU:NA和(S)-IBU:NA负载到MCM-41介孔二氧化硅颗粒(MSP)的孔中。通过核磁共振光谱分析了该过程的进展和效率。已证实TSF方法是一种用活性药物成分(API)填充MSP孔的有效且安全的技术。通过分析核磁共振结果,进一步证明了在熔融和冷却过程中未嵌入孔中的过量IBU和NA成分,会在MCM-41壁上结晶,保持非常特定的排列,这是晶体样品的特征。通过研究仅在孔内含有活性成分的(R/S)-IBU/MCM-41、(S)-IBU:NA/MCM-41和(R/S)-IBU:NA/MCM-41样品的释放动力学,发现与孔内含有IBU和NA的样品相比,第一个样品中IBU的释放速度要快得多。以苯甲酸(BA)作为共形成物的(R/S)-IBU:BA/MCM-41样品的研究进一步支持了API释放速率可由嵌入MSP孔中的共晶体的特定组成控制这一假设。